All In MedTech

Device Trial Radar · NCT07296263

Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

Dec 30, 2025

Primary completion

Sep 15, 2026

Study completion Sep 15, 2026

Sponsor

Lead sponsor
HyperfineNot on our public-company list
Sponsor type
Industry
First posted
Dec 22, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, interventional study designed to evaluate the visualization benefits of FDA approved gadolinium-based contrast agents (GBCAs) in portable magnetic resonance imaging (pMRI) of the brain. The study will enroll adult patients with known or suspected brain lesions involving blood-brain barrier disruption. Each participant will undergo a pre-contrast pMRI scan, receive an intravenous GBCA injection, and then complete a post-contrast pMRI scan using the Swoop® Portable MR Imaging® System. Lesion visualization will be assessed by independent neuroradiologists using standardized scoring criteria. The study will be conducted across a minimum of three sites to ensure diversity in patient population, imaging environments, and GBCA types.

Conditions

  • Intra-axial Tumors
  • Extra-axial Tumors
  • Infection/Inflammatory Lesions

Interventions

  • Portable MRI (pMRI)Device

    Portable magnetic resonance imaging (pMRI) performed using the Swoop® Portable MR Imaging® System (0.064 T), including acquisition of pre-contrast and post-contrast images.

  • Gadolinium-Based Contrast Agent (GBCA)Drug

    Intravenous administration of an FDA-approved gadolinium-based contrast agent (GBCA) according to institutional standard-of-care dosing, administered between pre-contrast and post-contrast pMRI imaging.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiologist-rated lesion border delineation on post-contrast portable MRITime frame: 6 months
  2. Radiologist-rated lesion internal morphology visibility on post-contrast portable MRITime frame: 6 months
  3. Radiologist-rated degree of contrast enhancement of target lesions on portable MRITime frame: 6 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Neurology of Central Florida Research Center

    Altamonte Springs, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dent Neurologic Institute

    Amherst, New York

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.